The Fast Track designation de-risks the anal cancer program and provides rolling review and Priority Review eligibility. Monitor for initiation of a pivotal study, partnership announcements, and upcoming data readouts. The stock may react positively near-term but long-term value depends on clinical execution.
Price Chart
Executive Summary
Oncolytics Biotech announced FDA Fast Track Designation for pelareorep in combination with a checkpoint inhibitor for second-line and later anal cancer (SCAC). This is the third Fast Track designation in gastrointestinal cancers, supporting a registrational pathway in an indication with no FDA-approved therapies and an estimated $1 billion U.S. market opportunity.
Key Facts
- FDA granted Fast Track Designation for pelareorep + checkpoint inhibitor in inoperable, locally recurrent or metastatic SCAC after prior systemic therapy.
- Third Fast Track designation in GI cancers (colorectal, pancreatic, anal).
- GOBLET study data: ORR ~30%, median DOR ~15.5 months, 12-month OS 82% vs 45.7% historical.
- No FDA-approved therapies exist for patients progressing after first-line standard of care in SCAC.
- Company believes it has a clear regulatory framework for a pivotal study following April 2026 FDA meeting.
Financial Impact
Estimated U.S. commercial opportunity approaching $1 billion annually per company press release; no company-reported financial figures in filing.
Risk Factors
- Clinical trial risk: pivotal study may fail to meet endpoints.
- Financing risk: clinical-stage company may need to raise capital to fund development.
- Competitive risk: other therapies may emerge for SCAC.
- Regulatory risk: Fast Track does not guarantee approval.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001129928-26-000045 |
| Document: oncolyticsscacfasttrack.htm | 0001129928-26-000045 |
| Document: 0001129928-26-000045-index-headers.html | 0001129928-26-000045 |
| Document: 0001129928-26-000045-index.html | 0001129928-26-000045 |
| Document: 0001129928-26-000045.txt | 0001129928-26-000045 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | 8-K | $0.7720 $0.7700 | ▼ −0.26% | ▲ +0.24% | $0.6310 (−18.26%) |
Jul 20, 2026 10w ago | 8-K | $0.8500 $0.8122 | ▼ −4.45% | ▼ −4.02% | $0.6310 (−25.76%) |
Jul 13, 2026 11w ago | 8-K | $0.9289 $0.8533 | ▼ −8.14% | ▼ −7.35% | $0.6310 (−32.07%) |
Jun 16, 2026 15w ago | 8-K | $0.9495 $0.9409 | ▼ −0.91% | ▲ +1.33% | $0.6310 (−33.54%) |
Jun 2, 2026 17w ago | 8-K | $0.9300 $0.8100 | ▼ −12.90% | ▼ −9.94% | $0.6310 (−32.15%) |
Jun 1, 2026 17w ago | 8-K | $1.06 $0.8400 | ▼ −20.75% | ▼ −18.00% | $0.6310 (−40.47%) |
May 22, 2026 19w ago | 8-K | $0.8100 $1.06 | ▲ +30.86% | ▲ +29.19% | $0.6310 (−22.10%) |
May 22, 2026 19w ago | Press Release | $0.8100 $1.06 | ▲ +30.86% | ▲ +29.19% | $0.6310 (−22.10%) |
Apr 27, 2026 22w ago | 8-K | $0.9700 $0.9300 | ▼ −4.12% | ▼ −4.52% | $0.6310 (−34.95%) |
Apr 6, 2026 25w ago | 424B5 | $0.9000 $1.02 | ▼ −13.33% | ▼ −8.00% | $0.6310 (+29.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access